Episode Details

Many cancer patients face a dual challenge: battling the tumor and an invisible enemy—infections from mold and mycotoxins. 

Dr. Prato explores how water-damaged buildings can harbor toxic mold, often overlooked by standard oncology practices. We highlight the critical need to address environmental health factors like mold exposure as potential root causes, ensuring comprehensive patient care alongside traditional cancer treatment.

🎯 What You’ll Learn in This Episode:
- The difference between mold spores and mycotoxins
- How mold exposure can stress the immune system
- What CIRS (chronic inflammatory response syndrome) means
- Why inflammation complicates cancer recovery
- The role of binders and detox support (under medical care)
- What MARCoNS biofilm infections are
- Why immune balance (TH1/TH2) matters
- The right questions to ask about mold testing

📍 Envita Medical Centers – Scottsdale, AZ
🌐 Learn more: www.envita.com
📞 Speak with a care coordinator: 866-830-4576

“You can’t rebuild immunity while something is quietly breaking it.”

Disclaimer
This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied.
________________________________________
Outcomes Disclaimer
The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.

You can read the full peer-reviewed study at: 

https://www.scirp.org/journal/paperinformation?paperid=132493